Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein Occlusion
Shots:
- The P-III QUASAR study of Eylea HD [Q8W, post 3 (n=293) or 5 (n=298) initial monthly doses] vs Eylea (Q4W; n=301) for macular edema secondary to RVO (central, branch & hemiretinal), achieved its 1EP at 36wks. sBLA for the same will be submitted in Q1’25
- Study depicted mean BCVA improvement of 17 (3 initial monthly doses) & 19.1 letters (5 initial monthly doses) with Eylea HD while 17.8 letters with Eylea. Mean observed BCVA was 72.8 (3 initial monthly doses) & 74.6 letters (5 initial monthly doses) with Eylea HD while 72 letters with Eylea
- Eylea HD (Eylea 8mg in the EU & Japan) is developed by Regeneron (exclusive US rights) & Bayer (exclusive rights outside the US), with both companies sharing profits equally
Ref: Regeneron | Image: Regeneron
Related News:- Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
